Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or... LETTERS MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill? na recent article in the American Journal of Neuroradiology, by these treatments. However, it raises the question of whether ICogswell et al urged radiologists to learn about amyloid-related MR imaging is the right technique for the purpose. In the pub- imaging abnormalities (ARIAs) and their MR imaging appearance lished drug trials, the significance of ARIAs is minimized and to be able to diagnose and monitor cerebral changes observed in considered to be reversible, as assessed from MR imaging. patients with Alzheimer disease treated with amyloid-targeting However, this is not a gospel truth; instead, the ARIAs are severe monoclonal antibodies. These include aducanumab (marketed as adverse effects of the treatment, demanding a thorough investiga- Aduhelm; Biogen), approved by the FDA, and a number of similar tion, including their long-term significance for patients. treatments currently in clinical trials, eg, donanemab (Eli Lilly), What is necessary in this connection is to establish the func- lecanemab (Eisai), gantenerumab (Hoffmann-La Roche), and so tional impact of the treatment with the FDA/CMS-approved forth. FDG-PET scans, demonstrating regional cortical glucose metabo- Common to these drugs is the lack of convincing evidence lism as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Neuroradiology American Journal of Neuroradiology

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

Download PDF
2 pages

Loading next page...
 
/lp/american-journal-of-neuroradiology/mri-monitoring-of-anti-alzheimer-therapy-amyloid-related-imaging-k9BnOK3ZJy

References (4)

Publisher
American Journal of Neuroradiology
Copyright
© 2023 by American Journal of Neuroradiology
ISSN
0195-6108
eISSN
1936-959X
DOI
10.3174/ajnr.a7702
Publisher site
See Article on Publisher Site

Abstract

LETTERS MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill? na recent article in the American Journal of Neuroradiology, by these treatments. However, it raises the question of whether ICogswell et al urged radiologists to learn about amyloid-related MR imaging is the right technique for the purpose. In the pub- imaging abnormalities (ARIAs) and their MR imaging appearance lished drug trials, the significance of ARIAs is minimized and to be able to diagnose and monitor cerebral changes observed in considered to be reversible, as assessed from MR imaging. patients with Alzheimer disease treated with amyloid-targeting However, this is not a gospel truth; instead, the ARIAs are severe monoclonal antibodies. These include aducanumab (marketed as adverse effects of the treatment, demanding a thorough investiga- Aduhelm; Biogen), approved by the FDA, and a number of similar tion, including their long-term significance for patients. treatments currently in clinical trials, eg, donanemab (Eli Lilly), What is necessary in this connection is to establish the func- lecanemab (Eisai), gantenerumab (Hoffmann-La Roche), and so tional impact of the treatment with the FDA/CMS-approved forth. FDG-PET scans, demonstrating regional cortical glucose metabo- Common to these drugs is the lack of convincing evidence lism as

Journal

American Journal of Neuroradiology – American Journal of Neuroradiology

Published: Jan 1, 2023

There are no references for this article.